Outlook Therapeutics的空头股数在12月下跌了15%，股价上涨，分析师将其评为“适度买入”。 Outlook Therapeutics' short interest fell 15% in December, with shares rising and analysts rating it a "Moderate Buy."

12月, " 展望治疗 " (OtLK)短期利息下降15%,股份增加0.31美元至2.01美元。 Outlook Therapeutics (OTLK) saw short interest drop by 15% in December, with shares gaining $0.31 to $2.01. 该公司的主要产品ONS-5010正在进行第三期试验,用于治疗黄斑退化. The company's lead product, ONS-5010, is in Phase-III trials for treating macular degeneration. 最近，Outlook Therapeutics 的收益预期超出预期 0.06 美元，分析师给予其“适度买入”评级和 32.73 美元的目标价。 Recently, Outlook Therapeutics beat earnings estimates by $0.06, with analysts giving it a "Moderate Buy" rating and a target price of $32.73.